生物标记相关各种联盟契约:契约动向、企业、财务条件

本报告提供生物标记相关各种联盟契约的相关调查，对近几年的联盟契约趋势，交易类型、治疗领域、技术等各种区分的明细，联盟契约的财务的条件，主要的大型契约，联盟契约积极的企业，联盟处企业的企业简介等彙整资料。

摘要整理

第1章 简介

第2章 生物标记相关的各种契约动向

• 简介
• 过去的联盟趋势
• 联盟活动最活跃的经营者
• 联盟趋势:各交易类型
• 联盟趋势:各治疗领域
• 联盟契约条件
  • 契约总额
  • 预付款金
  • 里程碑 (每到达目标) 支付金
  • 权利金比率

第4章 最活跃的经营者

• 简介
• 最活跃的经营者
• 联盟企业的企业简介

第5章 生物标记契约名录

第6章 生物标记契约:各技术类型

第7章 联盟资源中心

• 线上
• 活动
• 参考文献

附录

图表

Description

Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 463 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of biomarker dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.

Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse biomarker collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Biomarker Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of biomarker trends and structure of deals entered into by leading biopharma companies worldwide.

Biomarker Collaboration and Licensing Deals includes:

• Trends in biomarker dealmaking in the biopharma industry
• Directory of biomarker deal records covering pharmaceutical and biotechnology
• The leading biomarker deals by value
• Most active biomarker licensing dealmakers
• Biomarker Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse biomarker collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

• 2.1. Introduction
• 2.2. Biomarker deals over the years
• 2.3. Most active biomarker dealmakers
• 2.4. Biomarker deals by deal type
• 2.5. Biomarker deals by therapy area
• 2.6. Biomarker deals by industry sector
• 2.7. Deal terms for biomarker deals
  • 2.7.1 Biomarker deals headline values
  • 2.7.2 Biomarker deal upfront payments
  • 2.7.3 Biomarker deal milestone payments
  • 2.7.4 Biomarker royalty rates

Chapter 3 - Leading biomarker deals

• 3.1. Introduction
• 3.2. Top biomarker deals by value

Chapter 4 - Most active biomarker dealmakers

• 4.1. Introduction
• 4.2. Most active biomarker dealmakers
• 4.3. Most active biomarker deals company profiles

Chapter 5 - Biomarker contracts dealmaking directory

• 5.1. Introduction
• 5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

• Deal directory
• Deal directory - Biomarker deals by company A-Z
• Deal directory - Biomarker deals by deal type
• Deal directory - Biomarker deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Biomarker deals since 2016
• Figure 2: Active biomarker dealmaking activity - 2016 - 2023
• Figure 3: Biomarker deals by deal type since 2016
• Figure 4: Biomarker deals by therapy area since 2016
• Figure 5: Biomarker deals by industry sector since 2016
• Figure 6: Biomarker deals with a headline value
• Figure 7: Biomarker deals with an upfront value
• Figure 8: Biomarker deals with a milestone value
• Figure 9: Biomarker deals with a royalty rate value
• Figure 10: Top biomarker deals by value since 2016
• Figure 11: Most active biomarker dealmakers 2016 - 2023
• Figure 12: Biomarker deals by technology type since 2016